Bound homocysteine, cysteine, and cysteinylglycine distribution between albumin and globulins

Clinical Chemistry

Volumn 52, Issue 12, 2006, Pages 2258-2264

  Hortin, Glen L ^a   Seam, Nitin ^a   Hoehn, Gerard T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BINDING PROTEIN; CYSTEINE; CYSTEINYLGLYCINE; DISULFIDE; GLOBULIN; GLUTATHIONE; HOMOCYSTEINE; OROSOMUCOID; TRANSFERRIN;

AMINO ACID BLOOD LEVEL; ARTICLE; BINDING AFFINITY; COVALENT BOND; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KINETICS; NORMAL HUMAN; PROTEIN ANALYSIS; PROTEIN PURIFICATION; SERUM;

ADULT; CYSTEINE; DIPEPTIDES; DISULFIDES; HOMOCYSTEINE; HUMANS; PLASMA; PROTEIN BINDING; SERUM; SERUM ALBUMIN; SERUM GLOBULINS; SULFHYDRYL COMPOUNDS;

EID: 33845533655     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.074302     Document Type: Article

References (37)

1. Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 2004;148:34-40.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
3. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
4. El-Khairy L, Ueland PM, Refsum H, Graham IM, Vollset SE, European Concerted Action Project. Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. Circulation 2001;103:2544-9.
5. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
6. Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995;41:340-2.
7. Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Budy B, et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 2001;276:30111-7.
8. Jacobsen DW, Catanescu O, Dibello PM, Barbato JC. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis. Clin Chem Lab Med 2005;43:1076-83,
9. Jakubowski H. Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J Biol Chem 2002;277:30425-8.
10. Peters T Jr. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, CA: Academic Press, 1996:48-75.
11. Zinellu A, Sotgia S, Deianna L, Carru C. Quantification of thiol-containing amino acids linked by disulfides to LDL. Clin Chem 2005;51:658-60.
12. Lim A, Sengupta S, McComb ME, Theberge R, Wilson WG, Costello CE, et al. In vitro and in vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem 2003;278:49707-13.
13. Nepomuceno AI, Mason CJ, Muddiman DC, Berger HR III, Zeldenrust SR. Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization Fourier-transform ion cyclotron resonance mass spectrometry. Clin Chem 2004;50:1535-43.
14. Schweigert FJ, Wirth K, Raila J. Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci 2004;2:5.
15. Sass JO, Nakanishi T, Sato T, Sperl W, Shimizu A. S-homocysteinylation of transthyretin is detected in plasma and serum of humans with different types of hyperhomocysteinemia. Biochem Biophys Res Commun 2003;310:242-6.
16. Zhang Q, Kelly JW. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry 2003;42:8756-61.
17. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A 2005;102:10852-7.
18. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006;52:1223-37.
19. Huang L, Harvie G, Feitelson JS, Gramatikoff K, Herold DA, Allen DL, et al. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 2005;5:3314-28.
20. Gotto AM Jr., Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. Methods Enzymol 1986;128:3-41.
21. Hortin GL, Sullivan P, Csako GA. Relationships of plasma homocysteine to cysteine and albumin levels: potential utility of assessing cysteine levels. Clin Chem 2001;47:1121-4.
22. Hortin GL, Remaley AT. Mass determination of major plasma proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Clin Proteomics In press.
23. Bielicki JK, Forte TM, McCall MR, Stoltzfus LJ, Chiesa G, Sirtori CR, et al. High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice. J Lipid Res 1997;38:2314-21.
24. Perez-Mendez O, Bruckert E, Franceschini G, Duhal N, Lacroix B, Bonte JP, et al. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis 2000;148:317-25.
25. Penders J, Delanghe JR. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta 2004;346:107-18.
26. 1-acid glycoprotein. EMBO J 1987;6:2289-96.
27. 1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol 1998;54:129-38.
28. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 1999;12:439-46.
29. Bass R, Ruddock LW, Klappa P, Freedman RB. A major fraction of endoplasmic reticulum-located glutathione is present as mixed disulfides with protein. J Biol Chem 2004;279:5257-62.
30. Corti A, Paolicchi A, Franzini M, Dominici S, Casini AF, Pompella A. The S-thiolating activity of membrane gamma-glutamyltransferase: formation of cysteinyl-glycine mixed disulfides with cellular proteins and in the cell microenvironment. Antioxid Redox Signal 2005;7:911-8.
31. Sauls DL, Wolberg AS, Huffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 2003;1:300-6.
32. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol. 2006 Mar 30; [Epub ahead of print],
33. Steinmann C, Bogli C, Jungo M, Lammle B, Heinemann G, Wermuth B, et al. A new substitution, gamma 358 Ser→Cys, in fibrinogen Milano VII causes defective fibrin polymerization. Blood 1994;84:1874-80.
34. Mahley RW, Rail SC Jr. Apolipoprotein E. far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-37.
35. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 protein in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem 1996;34:517-20.
36. Putnam FW. α, β, γ, ω-the roster of the plasma proteins. In: Putnam FW, ed. The Plasma Proteins, 2nd ed., Vol. 1. New York: Academic Press, 1975:57-130.
37. Rassart E, Bedirian A, Do Carmo S, Guinard O, Sirois J, Terrisse L, et al. Apolipoprotein D. Biochim Biophys Acta 2000;1482:185-98.